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The proliferation and differentiation of B cells have been shown to be under 
the influence of many factors.  In  particular,  interleukin  1  (IL-1) and  B  cell- 
stimulatory factor (BSF) have been shown to play significant roles in the activation 
of B cells (1). Although interleukin 2 (IL-2 or T  cell growth factor) is important 
in  T  cell  proliferation,  its  role  in  B  cell  activation  remains  uncertain.  Some 
investigators suggest that IL-2 might be directly involved in B cell activation (2, 
3), while others (4,  5) indicate that its action on B cells is indirect, inducing T 
cells to secrete BSF and other helper factors. 
Uchiyama et al. (6) produced a  monoclonal antibody, anti-Tac. This antibody 
was shown to react with the IL-2 receptor (7). In the present study, we established 
a  monoclonal antibody, AT-l, with reactivities similar to anti-Tac. With AT-l, 
activated normal human B  cells were shown to express  IL-2 receptors.  These 
activated B cells proliferated in the presence of recombinant IL-2 (rIL-2). 
Materials and Methods 
Cell  Preparation.  Peripheral  blood mononuclear cells were isolated from leukocyte 
concentrates from normal donors, and tonsiilar single-cell preparations were made from 
tonsils removed from patients undergoing tonsillectomy. Separation of sheep erythrocyte 
(SRBC) rosette-forming cells and monocytes from B cells was done as described (8). The 
resulting non-T cells from peripheral blood contained 60-80% membrane Ig (mIg)  ÷ cells 
with <0.5%  T  cells.  The resulting non-T cells  from tonsils were  90-95%  mIg  ÷ with 
<0.5% T  cells. For simplicity, these non-T preparations will be referred to as B cells. 
B  Cell Activation.  Affinity-purified F(ab)'2  rabbit anti-IgM antibodies were prepared 
as described (8). 10-25 #g/ml of this preparation, which was used in the majority of the 
experiments, did not give substantial stimulation of resting B cells, rIL-2 was purchased 
from  Genzyme,  Boston,  MA.  Lymphokine preparations  were  either  purchased  from 
Electro-Nucleonics, Inc., Silver Springs, MD or prepared in our laboratory. In the latter 
case, pooled mononuclear cells were stimulated with 10 ~g/ml PHA-P (phytohemagglu- 
tinin) (Difco Laboratories, Inc., Detroit, MI) and 1% pokeweed mitogen (PWM) (Gibco 
Laboratories, Grand Island, NY). After 48 h, the supernatant was subjected to (NH4)2SO4 
precipitation at 30-80%  saturation. The precipitate was dissolved in 0.1  M phosphate 
buffer, pH 7.4. After dialysis against this buffer, the dissolved proteins were fractionated 
on a  DE52  column with a  salt gradient (0-0.3  M NaCI).  Fractions containing B cell 
stimulatory activity were pooled.  This pooled preparation  contained IL-2 and  B  cell 
differentiation factor(s) (termed CM-BSF). For B cell activation, 10% CM-BSF was used 
in conjunction with anti-IgM antibodies. Other mitogens were used at 0.005% vol/vol, 
for formalin-treated Staphylococcus aureus (a gift from Dr. S. Pahwa, North Shore Hospital, 
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Manhasett,  NY), 20% vol/vol with B95-8 supernatant as a source of Epstein-Barr virus 
(EBV), and 1% vol/voi for PWM. 
Monoclonal Antibody Production.  BC~F~  females were immunized with PHA-activated 
T cells. Their spleen cells were fused with SP2/0 tumor cells. Hybridoma supernatants 
were screened for their binding activity and blocking activity of T cell proliferation.  The 
desired hybridomas  were  cloned  on soft agar.  Details of these  procedures  have  been 
described previously (9). 
Immunofluoreseenee Studies.  Activated B cells were analyzed for IL-2 receptor expres- 
sion by two-color fluorescence microscopy. Activated cells were stained with AT-1 at 4 °C 
for 30 min. After extensive washings, the cells were stained for 30 min, with a fluorescein 
isothiocyanate-conjugated  goat anti-mouse Ig to identify the AT-1 + cells and rhodamine- 
conjugated anti-human IgM to identify B cells. After further washings, slides were made 
for fluorescence microscopy. For certain experiments  involving only one color, the cells 
were analyzed with a Coulter Epics V flow cytometer (Coulter Electronics, Hialeah, FL). 
Integrated fluorescence  of the gated population  was measured  and  10,000 cells were 
analyzed. 
Other Assays.  Lymphocyte proliferation  assays and reverse  plaque  assays were  per- 
formed as described previously (10). For cell iodination and labeling with [sSS]methionine 
as well as immunoprecipitation  and autoradiography, they were performed as described 
(11, 12). 
Results 
Identification ofp60-65 (Tac Antigen) by Monoclonal Antibody AT-1.  Two mono- 
clonal antibodies against activated human T  cells were found to precipitate a 
p60-65 molecule from activated T  cells.  One of these, AT-l, an IgG1 antibody, 
was  studied  in  detail.  It  inhibited  mitogen-  and  alloantigen-induced T  cell 
proliferation as well as IL-2-dependent proliferation of T  blasts. Immunoprecip- 
itation revealed that AT-1  and anti-Tac, kindly provided by Dr. T. Waldmann 
and Dr. T. Uchiyama, precipitated similar p60-65 molecules on activated T  cells 
(Fig.  1, lanes I  and 2).  After clearance with anti-Tac, either AT-1  or anti-Tac 
did not precipitate any molecule from the lysate of activated T  cells (Fig. 1, lanes 
3  and 4).  The reciprocal experiment showed similar results. Thus,  AT-1  and 
anti-Tac bound to an identical protein on activated T  cells. 
Immunofluorescence  and Biosynthetic Studies ofp60-65 Expression  on Activated B 
Cells.  To define the reactivity of AT-l, a  variety of target cells were used in 
immunofluorescence studies.  AT-1  readily stained B blasts generated by anti- 
IgM antibody activation and CM-BSF. The cell preparation was shown to be free 
of SRBC rosette-forming cells (T cells).  To show that the p60-65  molecule was 
synthesized by the activated B  cells,  we  incubated them  for  16  h  with  [~S]- 
methionine. A p60-65 molecule was precipitated by AT-1 from the cell lysate of 
these B blasts (Fig. 2, lane 4).  For comparison, the p60-65 molecule precipitated 
from PHA-activated T  blasts is shown on lane 2 of Fig. 2. 
The kinetics of p60-65 expression by B blasts stimulated by anti-IgM and CM- 
BSF were studied (Fig. 3). Resting B cells did not stain for IL-2 receptors (Fig. 
3A). As early as  12 h  after activation, a  minor population of B cells stained by 
AT-1 (Fig. 3B). By 60 h, >50% of the B blasts were positive. Further incubation 
did not increase the positivity of  the B blasts. At these time intervals, the activated 
B blasts were shown to be free of T  cells and stained for membrane IgM. 
The  expression  of p60-65  by  B  blasts  was not  dependent on  the  mode of 
activation. By two-color fluorochrome analysis, tonsillar B cells activated by three 
different mitogens were able to express IL-2 receptors (Table I). It is of interest JUNG,  HARA,  AND  FU  BRIEF  DEFINITIVE  REPORT  1599 
FIGURE  1  FIGURE 2 
FIGURE  l.  Immunoprecipitation of p60-65 by AT-1 and anti-Tac. II25-1abeled polypeptides 
precipitated by AT-I (lane I) and by anti-Tac (lane 2). No precipitated peptides were detected 
by either AT-1 (lane 3) or anti-Tac (lane 4) after the cell lysate was cleared with anti-Tac. 
FIGURE 2.  p60-65 molecules from activated  T  and B  lymphocytes.  1  X  107 activated T 
lymphocytes and 2  x  107 activated B blasts were labeled with [35S]methionine. Lysates were 
immunoprecipitated with control antibody and AT-1. No proteins were precipitated by the 
control antibody (lane 1 for T  blasts and lane 3 for B blasts), p60-65 molecules were brought 
down by AT-1 from lysates of T  blasts (lane 2) and B blasts (lane 4). 
to  note  that  the  maximal  expression  was  seen  at  day  5  of activation  when 
formalinized staphylococci and EBV were used as activators. Peripheral blood B 
cells were also able to express IL-2 receptors when stimulated with anti-IgM and 
CM-BSF or with PWM in the presence of T  cells. 
Effect of rlL-2 on Activated B  Cells.  rIL-2 was assayed with PHA-stimulated T 
blasts.  Maximum stimulation  was obtained at 250-500  U/ml as defined by the 
manufacturer. At 250 U/ml, rIL-2 did not stimulate tonsillar B cells to proliferate 
(376 vs. 846 cpm for medium control). With anti-IgM at 10/~g/ml, rIL-2 showed 
minimal effect (706 cpm). With this dose of anti-IgM and  10% CM-BSF, signifi- 
cant  proliferation  was  detected  (11,117  cpm).  Repeated  experiments  showed 
similar results, indicating rIL-2 had no effect on resting B cells. 
To determine  the effect of rIL-2  on  activated B  cells,  tonsillar  B  cells were 
first activated  with anti-IgM  and  CM-BSF for  3  d.  The activated B  cells were 
further treated with SRBC and Ficoll-Hypaque gradient sedimentation to deplete 
possible contaminating  T  cells.  The  remaining  B  blasts  were  cultured  in  the 
presence of rIL-2 and assayed for proliferation at various time intervals (Exp.  1, 
Table II). Significant proliferation  was seen in the presence of rIL-2 at all time 
intervals.  No  SRBC  rosette-forming  cells  were  detected  after  rIL-2  induced 
proliferation in these cultures. Similar results were obtained in experiment 2. In 
general, rIL-2 induced less vigorous proliferation than CM-BSF. 
The effects of rIL-2  on B cell differentiation  to Ig-secreting cells or plaque- 
forming  cells  (PFC)  were  also  investigated.  The  addition  of  10%  CM-BSF  to 1600  JUNG,  HARA,  AND  FU  BRIEF  DEFINITIVE  REPORT 
m  '5 
"-I  Oh 
Z 
~  c 
W 
0 









FIGURE  3.  Cytofluorometric analysis of IL-2 receptor expression by human tonsillar B cells 
activated by anti-IgM and CM-BSF: (  ) staining with control antibody, and (---)  staining 
with antibody AT-1. 
TABLE  I 
Expression of lL-2 Receptors on B Cells Activated by Various Mitogens 
Cell source  Stimulation 
Time of examination after activation 
Day 3  Day 5 
% 
Tonsil B cells  Anti-IgM  (25  ttg/ml)  +  10%  45.4 (35.4-50.1)  ND 
CM-BSF 
S. aureus  31.1 (21.8-48.5)  47.4 (35-59.7) 
EBV  6.9  (1.5-16.7)  42.8 (38.2-49.5) 
Mononuclear cells  PWM  33.9 (17.1-46.5)  ND 
PBL B cells  Anti-lgM  (25  #g/ml)  +  CM-  50.2 (39.8-57.2)  ND 
BSF 
ND, not done; PBL, peripheral blood leukocytes. 
TABLE  II 
Effect of rlL-2 on Activated B Cells 
Experiment  Time 
Agents added 
rlL-2 
Medium  (500 U/ml) 
2  24 
h  qnn 
24  8,988  18,329 
48  1,221  10,503 
60  1,332  8,561 
rlL-2 added  cpm 
U/ml 
O  1,752 
100  4,287 
200  6,702 
500  5,605 
10% CM-BSF  20,690 
Tonsillar B cells were activated with rabbit anti-IgM (25 ~g/ml) with 10% CM-BSF 
for 3 d. Cells were then washed three times and cell concentration adjusted to 10°/ 
ml.  105 cells/well  were cultured with rlL-2 added at the indicated concentrations 
and cells harvested at the indicated time. No T cells were detectable at the beginning 
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formalinized staphylococcus-stimulated B blasts induced 1,640  PFC/106,  while 
80  PFC/106  were  detected in  the  control  culture.  Addition  of rIL-2  to  the 
activated B blasts did not increase PFC significantly (145  PFC/106 with 200  U 
rlL-2/ml). These results were confirmed in two additional experiments. Attempts 
to demonstrate synergy between a  low dose of CM-BSF and rIL-2 gave varied 
results. In the best experiment, a twofold increase in PFC was seen when rIL-2 
was added to a culture containing a suboptimal dose of CM-BSF. 
Discussion 
In the present investigation, monoclonal antibody AT-1  is shown to identify 
the putative [L-2 receptor (p60-65). The molecular weight was higher than that 
reported previously (7). The receptor of lower molecular weight was due to the 
expression of an aberrant receptor on HUT-102 cells (13). With this antibody, 
we have demonstrated the expression of IL-2 receptors by activated B cells by 
immunofluorescence and  biosynthetic studies.  Great  care  has  been  taken  to 
ensure that our B blast preparations were devoid of T  cells. The expression of 
IL-2  receptors by activated B  cells is thus firmly established.  Similar findings 
have been reported by others in a preliminary communication (14). 
rIL-2 is shown in this study to induce B blast  proliferation.  It appears  that 
three distinct interleukins (IL-1, IL-2, and BSF) play significant roles in B cell 
proliferation. They act at various times during B cell activation. BSF acts at 4-6 
h, IL-1 at 16-20 h (1), and IL-2 at 2-3 d, after activation. The contributions of 
these factors to B cell activation in vivo remain to be determined. 
The effect of IL-2  on the differentiation of B blasts  is less  clear. It can be 
concluded that IL-2 by itself induces little differentiation when added to activated 
blasts. Whether IL-2 can act synergistically with other helper factors on B cell 
differentiation needs to be resolved. This cannot be done unless various purified 
factors are available. 
Relevant to this discussion is our recent finding in a child with severe combined 
immunodeficiency. The child had IgM  ÷ B cells. These B cells expressed IL-2 
receptors upon activation by anti-IgM and B cell stimulation factors. However, 
the activated B cells failed to proliferate when IL-2 was added to the culture. 
These cells were also unable to differentiate in the presence of B cell differentia- 
tion factors. The failure to respond to IL-2 by IL-2 receptor-positive B blasts 
and the associated deficiency in this patient adds support tO the hypothesis that 
IL-2 plays significant roles in normal B cell activation and differentiation. 
Summary 
A  monoclonal  antibody,  AT-I,  is  shown  to  precipitate  a  p60-65  molecule 
identical to the Tac antigen.  With AT-I,  the expression of IL-2  receptors by 
normal activated human B cells from peripheral blood and tonsils is documented 
by biosynthetic and immunofluorescence studies.  AT-1  precipitated a  p60-65 
protein  from  [S~S]methionine-labeled activated  B  cells,  similar  to  that  from 
activated  T  cells.  The  interleukin  2  (IL-2)  receptor  appeared  shortly  after 
activation with anti-IgM and B cell-stimulatory factor(s). Its expression reached 
its peak at 60-72 h with -50% of the B blasts stained by AT-1. Other modes of 
activation of B cells, by T  cell-independent, formalin-treated staphylococci and 1602  JUNG,  HARA, AND  FU  BRIEF  DEFINITIVE  REPORT 
Epstein-Barr virus,  and  by T  ceil-dependent pokeweed mitogen, also induced 
IL-2 receptor expression. The functional significance of this finding was inves- 
tigated using recombinant  IL-2 (rIL-2). While rIL-2 did not induce resting B 
cells to proliferate in  the presence of anti-IgM,  it  induced activated B  cells to 
proliferate in  the  absence  of other factors.  On  the  other hand,  rIL-2  did  not 
induce the differentiation of these activated B iymphocytes. These data suggest 
that IL-2 may play a significant role in B cell activation. 
Received  for publication 19July 1984. 
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